antigen exemplary seq id nos description npc 1 npc (ATCC)

ATCC is a verified supplier

ATCC manufactures this product

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

ATCC antigen exemplary seq id nos description npc 1 npc
Antigen Exemplary Seq Id Nos Description Npc 1 Npc, supplied by ATCC, used in various techniques. Bioz Stars score: 97/100, based on 2531 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/antigen+exemplary+seq+id+nos+description+npc+1+npc/Antigen/us12454560-661-2-16
Average 97 stars, based on 2531 article reviews

antigen exemplary seq id nos description npc 1 npc - by Bioz Stars, 2026-09

97/100 stars

Images

Variant Assay:

Article Title: Colon and pancreas cancer peptidomimetics
Article Snippet: .. Antibody Aliases Antigen Exemplary SEQ ID NOs Description NPC-1 NPC-1 Murine hybridoma that expresses NPC-1 IgG1 (ATCC) NEO-101 NPC-1C, NPC-1 Light Chain (SEQ ID NOs: 57, 58) Chimeric NEO-101 antibody, ensituximab LC CDRs (SEQ ID NOs: 59-61) engineered in CHO-DG44 Heavy Chain (SEQ ID NOs: 62, 63) production cell clone 4B7; targets a HC CDRs (SEQ ID NOs: 64-66) variant of MUC5AC NEO-102 NPC-1 Light Chain (SEQ ID NOs: 67, 68) Chimeric NEO-101 antibody, LC CDRs (SEQ ID NOs: 69-71) engineered in CHO-M production Heavy Chain (SEQ ID NOs: 72, 73) cells, contains 2 amino acid changes HC CDRs (SEQ ID NOs: 74-76) in HC constant domain* NEO-103 NPC-1 Light Chain (SEQ ID NOs: 77,78) Humanized NEO-101 antibody Heavy Chain (SEQ ID NOs: 79, 80) Antibodies may comprise of two identical light polypeptide chains of molecular weight approximately 23,000 daltons (“light chain”), and two identical heavy chains of molecular weight 53,000-70,000 (“heavy chain”). ..

Article Title: Colon and pancreas cancer peptidomimetics
Article Snippet: .. Antibody Aliases Antigen Exemplary SEQ ID NOs Description NPC-1 NPC-1 Murine hybridoma that expresses NPC-1 IgG1 (ATCC) NEO-101 NPC-1C, NPC-1 Light Chain (SEQ ID NOs: 57, 58) Chimeric NEO-101 antibody, ensituximab LC CDRs (SEQ ID NOs: 59-61) engineered in CHO-DG44 Heavy Chain (SEQ ID NOs: 62, 63) production cell clone 4B7; targets a HC CDRs (SEQ ID NOs: 64-66) variant of MUC5AC NEO-102 NPC-1 Light Chain (SEQ ID NOs: 67, 68) Chimeric NEO-101 antibody, LC CDRs (SEQ ID NOs: 69-71) engineered in CHO-M production Heavy Chain (SEQ ID NOs: 72, 73) cells, contains 2 amino acid changes HC CDRs (SEQ ID NOs: 74-76) in HC constant domain* NEO-103 NPC-1 Light Chain (SEQ ID NOs: 77, 78) Humanized NEO-101 antibody Heavy Chain (SEQ ID NOs: 79, 80) Antibodies may comprise of two identical light polypeptide chains of molecular weight approximately 23,000 daltons (“light chain”), and two identical heavy chains of molecular weight 53,000-70,000 (“heavy chain”). ..

Article Title: Colon and pancreas cancer specific antigens and antibodies
Article Snippet: .. Antibody Aliases Antigen Exemplary SEQ ID NOs Description NPC-1 NPC-1 Murine hybridoma that expresses NPC-1 IgG1 (ATCC) NEO-101 NPC-1C, NPC-1 Light Chain (SEQ ID NOs: 51, 52) Chimeric NPC-1 antibody, ensituximab LC CDRs (SEQ ID NOs: 53-55) engineered in CHO-DG44 Heavy Chain (SEQ ID NOs: 56, 57) production cell clone 4B7; targets a HC CDRs (SEQ ID NOs: 58-60) variant of MUC5AC NEO-102 NPC-1 Light Chain (SEQ ID NOs: 61, 62) Chimeric NPC-1 antibody, LC CDRs (SEQ ID NOs: 63-65) engineered in CHO-M production Heavy Chain (SEQ ID NOs: 66, 67) cells, contains 2 amino acid changes HC CDRs (SEQ ID NOs: 68-70) in HC constant domain* NEO-103 NPC-1 Light Chain (SEQ ID NOs: 71, 72) Humanized NPC-1 antibody Heavy Chain (SEQ ID NOs: 73, 74) 16C3 16C3 Light Chain (SEQ ID NOs: 75, 76) Murine hybridoma that expresses LC CDRs (SEQ ID NOs: 77-79) 16C3 IgG1 (ATCC) Heavy Chain (SEQ ID NOs: 80, 81) HC CDRs (SEQ ID NOs: 82-84) 16C3 Variant h16C3 16C3 Light Chain (SEQ ID NOs: 85-89) Humanized 16C3 antibody antibodies Heavy Chain (SEQ ID NOs: 90-94) NEO-201 h16C3-Abb* 16C3 Light Chain (SEQ ID NOs: 95, 96) Humanized 16C3 antibody LC CDRs (SEQ ID NOs: 97-99) Heavy Chain (SEQ ID NOs: 100, 101) HC CDRs (SEQ ID NOs: 102-104) 31.1 31.1 Chimeric 31.1 antibody, produced in CHO-K cells NEO-301 31.1C 31.1 Light Chain (SEQ ID NO: 105) Chimeric 31.1 antibody, contains 2 Heavy Chain (SEQ ID NO: 106) amino acid changes in HC constant domain*, produced in high titer CHO-S cells NEO-302 31.1 Light Chain (SEQ ID NO: 107, 108) Humanized 31.1 antibody Heavy Chain (SEQ ID NO: 109, 110) *2 amino acid changes in heavy chain constant domain are Proline at residue 175 to Leucine in CH1 and Methionine at residue 390 to Threonine in CH3. ..

Article Title: Colon and pancreas cancer peptidomimetics
Article Snippet: .. Antibody Aliases Antigen Exemplary SEQ ID NOs Description NPC-1 NPC-1 Murine hybridoma that expresses NPC-1 IgG1 (ATCC) NEO-101 NPC-1C, NPC-1 Light Chain (SEQ ID NOs: 57, 58) Chimeric NEO-101 antibody, ensituximab LC CDRs (SEQ ID NOs: 59-61) engineered in CHO-DG44 Heavy Chain (SEQ ID NOs: 62, 63) production cell clone 4B7; targets a HC CDRs (SEQ ID NOs: 64-66) variant of MUC5AC NEO-102 NPC-1 Light Chain (SEQ ID NOs: 67, 68) Chimeric NEO-101 antibody, LC CDRs (SEQ ID NOs: 69-71) engineered in CHO-M production Heavy Chain (SEQ ID NOs: 72, 73) cells, contains 2 amino acid changes HC CDRs (SEQ ID NOs: 74-76) in HC constant domain* NEO-103 NPC-1 Light Chain (SEQ ID NOs: 77, 78) Humanized NEO-101 antibody Heavy Chain (SEQ ID NOs: 79, 80) Antibodies may comprise of two identical light polypeptide chains of molecular weight approximately 23,000 daltons (“light chain”), and two identical heavy chains of molecular weight 53,000-70,000 (“heavy chain”). ..

Article Title: Humanized monoclonal antibodies and methods of use for the diagnosis and treatment of colon and pancreas cancer
Article Snippet: .. TABLE 1 Antibodies Antibody Aliases Antigen Exemplary SEQ ID NOs Description NPC-1 NPC-1 Murine hybridoma that expresses NPC-1 IgG1 (ATCC) NEO-101 NPC-1C, NPC-1 Light Chain (SEQ ID NOs: 14, Chimeric NPC-1 antibody, ensituximab 15) engineered in CHO-DG44 LC CDRs (SEQ ID NOs: 16, 17, production cell clone 4B7; 18 targets a variant of MUC5AC Heavy Chain (SEQ ID NOs: 19, 20) HC CDRs (SEQ ID NOs: 21, 22, 23) NEO-102 NPC-1 Light Chain (SEQ ID NOs: 24, Chimeric NPC-1 antibody, 25) engineered in CHO-M LC CDRs (SEQ ID NOs: 26, 27, production cells, contains 2 28) amino acid changes in HC Heavy Chain (SEQ ID NOs: 29, constant domain* 30) HC CDRs (SEQ ID NOs: 31, 32, 33) NEO-103 NPC-1 Light Chain (SEQ ID NOs: 34, Humanized NPC-1 antibody 35) Heavy Chain (SEQ ID NOs: 36, 37) 16C3 16C3 Light Chain (SEQ ID NOs: 38, Murine hybridoma that 39) expresses 16C3 IgG1 (ATCC) LC CDRs (SEQ ID NOs: 40, 41, 42) Heavy Chain (SEQ ID NOs: 43, 44) HC CDRs (SEQ ID NOs: 45, 46, 47) 16C3 Variant 16C3 Light Chain (SEQ ID NOs: 48, Humanized 16C3 antibody h16C3 49, 50, 51, 52) antibodies Heavy Chain (SEQ ID NOs: 53, 54, 55, 56, 57) NEO-201 h16C3- 16C3 Light Chain (SEQ ID NOs: 58, Humanized 16C3 antibody Abb* 59) LC CDRs (SEQ ID NOs: 60, 61, 62) Heavy Chain (SEQ ID NOs: 63, 64) HC CDRs (SEQ ID NOs: 65, 66, 67) NEO-300 Antibodies 31.1 31.1 Chimeric 31.1 antibody, produced in CHO-K cells NEO-301 31.1C 31.1 Light Chain (SEQ ID NO: 68) Chimeric 31.1 antibody, Heavy Chain (SEQ ID NO: 69) contains 2 amino acid changes in HC constant domain,* produced in high titer CHO-S cells NEO-302 31.1 Light Chain (SEQ ID NO: 70, 71) Humanized 31.1 antibody Heavy Chain (SEQ ID NO: 72, 73) NGO-303 31.1 Heavy Chain (SEQ ID NOs: 74- Humanized 31.1 antibody 77) HC CDRs (SEQ ID NOs: 78-83) Light Chain (SEQ ID NOs: 84- 87) LC CDRs (SEQ ID NOs: 88-93) *2 amino acid changes in heavy chain constant domain are Proline at residue 175 to Leucine in CH1 and Methionine at residue 390 to Threonine in CH3. ..

Article Title: Humanized monoclonal antibodies and methods of use for the diagnosis and treatment of colon and pancreas cancer
Article Snippet: .. TABLE 1 Antibodies Antibody Aliases Antigen Exemplary SEQ ID NOs Description NPC-1 NPC-1 Murine hybridoma that expresses NPC-1 IgG1 (ATCC) NEO-101 NPC-1C, NPC-1 Light Chain (SEQ ID NOs: 14, 15) Chimeric NPC-1 antibody, ensituximab LC CDRs (SEQ ID NOs: 16, 17, 18 engineered in CHO-DG44 Heavy Chain (SEQ ID NOs: 19, 20) production cell clone 4B7; HC CDRs (SEQ ID NOs: 21, 22, 23) targets a variant of MUC5AC NEO-102 NPC-1 Light Chain (SEQ ID NOs: 24, 25) Chimeric NPC-1 antibody, LC CDRs (SEQ ID NOs: 26, 27, 28) engineered in CHO-M Heavy Chain (SEQ ID NOs: 29, 30) production cells, contains HC CDRs (SEQ ID NOs: 31,32, 33) 2 amino acid changes in HC constant domain* NEO-103 NPC-1 Light Chain (SEQ ID NOs: 34, 35) Humanized NPC-1 antibody Heavy Chain (SEQ ID NOs: 36, 37) 16C3 16C3 Light Chain (SEQ ID NOs: 38, 39) Murine hybridoma that LC CDRs (SEQ ID NOs: 40, 41, 42) expresses 16C3 IgG1 Heavy Chain (SEQ ID NOs: 43, 44) (ATCC) HC CDRs (SEQ ID NOs: 45, 46, 47) 16C3 Variant 16C3 Light Chain (SEQ ID NOs: 48, Humanized 16C3 antibody h16C3 49, 50, 51, 52) antibodies Heavy Chain (SEQ ID NOs: 53, 54, 55, 56, 57) NEO-201 h16C3-Abb* 16C3 Light Chain (SEQ ID NOs: 58, 59) Humanized 16C3 antibody LC CDRs (SEQ ID NOs: 60, 61, 62) Heavy Chain (SEQ ID NOs: 63, 64) HC CDRs (SEQ ID NOs: 65, 66, 67) NEO-300 Antibodies 31.1 31.1 Chimeric 31.1 antibody, produced in CHO-K cells NEO-301 31.1C 31.1 Light Chain (SEQ ID NO: 68) Chimeric 31.1 antibody, Heavy Chain (SEQ ID NO: 69) contains 2 amino acid changes in HC constant domain,* produced in high titer CHO-S cells NEO-302 31.1 Light Chain (SEQ ID NO: 70, 71) Humanized 31.1 antibody Heavy Chain (SEQ ID NO: 72, 73) NEO-303 31.1 Heavy Chain (SEQ ID NOs: 74-77) Humanized 31.1 antibody HC CDRs (SEQ ID NOs: 78-83) Light Chain (SEQ ID NOs: 84-87) LC CDRs (SEQ ID NOs: 88-93) *2 amino acid changes in heavy chain constant domain are Proline at residue 175 to Leucine in CH1 and Methionine at residue 390 to Threonine in CH3. ..

Article Title: Humanized monoclonal antibodies and methods of use for the diagnosis and treatment of colon and pancreas cancer
Article Snippet: .. TABLE 1 Antibodies Antibody Aliases Antigen Exemplary SEQ ID NOs Description NPC-1 NPC-1 Murine hybridoma that expresses NPC-1 IgG1 (ATCC) NEO-101 NPC-1C, NPC-1 Light Chain (SEQ ID NOs: 14, 15) Chimeric NPC-1 antibody, ensituximab LC CDRs (SEQ ID NOs: 16, 17, 18 engineered in CHO-DG44 Heavy Chain (SEQ ID NOs: 19, 20) production cell clone 4B7; HC CDRs (SEQ ID NOs: 21, 22, 23) targets a variant of MUC5AC NEO-102 NPC-1 Light Chain (SEQ ID NOs: 24, 25) Chimeric NPC-1 antibody, LC CDRs (SEQ ID NOs: 26, 27, 28) engineered in CHO-M Heavy Chain (SEQ ID NOs: 29, 30) production cells, contains 2 HC CDRs (SEQ ID NOs: 31, 32, 33) amino acid changes in HC constant domain* NEO-103 NPC-1 Light Chain (SEQ ID NOs: 34, 35) Humanized NPC-1 antibody Heavy Chain (SEQ ID NOs: 36, 37) 16C3 16C3 Light Chain (SEQ ID NOs: 38, 39) Murine hybridoma that LC CDRs (SEQ ID NOs: 40, 41, 42) expresses 16C3 IgG1 (ATCC) Heavy Chain (SEQ ID NOs: 43, 44) HC CDRs (SEQ ID NOs: 45, 46, 47) 16C3 Variant 16C3 Light Chain (SEQ ID NOs: 48, 49, Humanized 16C3 antibody h16C3 50, 51, 52) antibodies Heavy Chain (SEQ ID NOs: 53, 54, 55, 56, 57) NEO-201 h16C3- 16C3 Light Chain (SEQ ID NOs: 58, 59) Humanized 16C3 antibody Abb* LC CDRs (SEQ ID NOs: 60, 61, 62) Heavy Chain (SEQ ID NOs: 63, 64) HC CDRs (SEQ ID NOs: 65, 66, 67) NEO-300 Antibodies 31.1 31.1 Chimeric 31.1 antibody, produced in CHO-K cells NEO-301 31.1C 31.1 Light Chain (SEQ ID NO: 68) Chimeric 31.1 antibody, Heavy Chain (SEQ ID NO: 69) contains 2 amino acid changes in HC constant domain,* produced in high titer CHO-S cells NEO-302 31.1 Light Chain (SEQ ID NO: 70, 71) Humanized 31.1 antibody Heavy Chain (SEQ ID NO: 72, 73) NEO-303 31.1 Heavy Chain (SEQ ID NOs: 74-77) Humanized 31.1 antibody HC CDRs (SEQ ID NOs: 78-83) Light Chain (SEQ ID NOs: 84-87) LC CDRs (SEQ ID NOs: 88-93) *2 amino acid changes in heavy chain constant domain are Proline at residue 175 to Leucine in CH1 and Methionine at residue 390 to Threonine in CH3. ..

Molecular Weight:

Article Title: Colon and pancreas cancer peptidomimetics
Article Snippet: .. Antibody Aliases Antigen Exemplary SEQ ID NOs Description NPC-1 NPC-1 Murine hybridoma that expresses NPC-1 IgG1 (ATCC) NEO-101 NPC-1C, NPC-1 Light Chain (SEQ ID NOs: 57, 58) Chimeric NEO-101 antibody, ensituximab LC CDRs (SEQ ID NOs: 59-61) engineered in CHO-DG44 Heavy Chain (SEQ ID NOs: 62, 63) production cell clone 4B7; targets a HC CDRs (SEQ ID NOs: 64-66) variant of MUC5AC NEO-102 NPC-1 Light Chain (SEQ ID NOs: 67, 68) Chimeric NEO-101 antibody, LC CDRs (SEQ ID NOs: 69-71) engineered in CHO-M production Heavy Chain (SEQ ID NOs: 72, 73) cells, contains 2 amino acid changes HC CDRs (SEQ ID NOs: 74-76) in HC constant domain* NEO-103 NPC-1 Light Chain (SEQ ID NOs: 77, 78) Humanized NEO-101 antibody Heavy Chain (SEQ ID NOs: 79, 80) Antibodies may comprise of two identical light polypeptide chains of molecular weight approximately 23,000 daltons (“light chain”), and two identical heavy chains of molecular weight 53,000-70,000 (“heavy chain”). ..

Produced:

Article Title: Humanized monoclonal antibodies and methods of use for the diagnosis and treatment of colon and pancreas cancer
Article Snippet: .. TABLE 1 Antibodies Antibody Aliases Antigen Exemplary SEQ ID NOs Description NPC-1 NPC-1 Murine hybridoma that expresses NPC-1 IgG1 (ATCC) NEO-101 NPC-1C, NPC-1 Light Chain (SEQ ID NOs: 14, 15) Chimeric NPC-1 antibody, ensituximab LC CDRs (SEQ ID NOs: 16, 17, 18 engineered in CHO-DG44 Heavy Chain (SEQ ID NOs: 19, 20) production cell clone 4B7; HC CDRs (SEQ ID NOs: 21, 22, 23) targets a variant of MUC5AC NEO-102 NPC-1 Light Chain (SEQ ID NOs: 24, 25) Chimeric NPC-1 antibody, LC CDRs (SEQ ID NOs: 26, 27, 28) engineered in CHO-M Heavy Chain (SEQ ID NOs: 29, 30) production cells, contains HC CDRs (SEQ ID NOs: 31,32, 33) 2 amino acid changes in HC constant domain* NEO-103 NPC-1 Light Chain (SEQ ID NOs: 34, 35) Humanized NPC-1 antibody Heavy Chain (SEQ ID NOs: 36, 37) 16C3 16C3 Light Chain (SEQ ID NOs: 38, 39) Murine hybridoma that LC CDRs (SEQ ID NOs: 40, 41, 42) expresses 16C3 IgG1 Heavy Chain (SEQ ID NOs: 43, 44) (ATCC) HC CDRs (SEQ ID NOs: 45, 46, 47) 16C3 Variant 16C3 Light Chain (SEQ ID NOs: 48, Humanized 16C3 antibody h16C3 49, 50, 51, 52) antibodies Heavy Chain (SEQ ID NOs: 53, 54, 55, 56, 57) NEO-201 h16C3-Abb* 16C3 Light Chain (SEQ ID NOs: 58, 59) Humanized 16C3 antibody LC CDRs (SEQ ID NOs: 60, 61, 62) Heavy Chain (SEQ ID NOs: 63, 64) HC CDRs (SEQ ID NOs: 65, 66, 67) NEO-300 Antibodies 31.1 31.1 Chimeric 31.1 antibody, produced in CHO-K cells NEO-301 31.1C 31.1 Light Chain (SEQ ID NO: 68) Chimeric 31.1 antibody, Heavy Chain (SEQ ID NO: 69) contains 2 amino acid changes in HC constant domain,* produced in high titer CHO-S cells NEO-302 31.1 Light Chain (SEQ ID NO: 70, 71) Humanized 31.1 antibody Heavy Chain (SEQ ID NO: 72, 73) NEO-303 31.1 Heavy Chain (SEQ ID NOs: 74-77) Humanized 31.1 antibody HC CDRs (SEQ ID NOs: 78-83) Light Chain (SEQ ID NOs: 84-87) LC CDRs (SEQ ID NOs: 88-93) *2 amino acid changes in heavy chain constant domain are Proline at residue 175 to Leucine in CH1 and Methionine at residue 390 to Threonine in CH3. ..

Article Title: Humanized monoclonal antibodies and methods of use for the diagnosis and treatment of colon and pancreas cancer
Article Snippet: .. TABLE 1 Antibodies Antibody Aliases Antigen Exemplary SEQ ID NOs Description NPC-1 NPC-1 Murine hybridoma that expresses NPC-1 IgG1 (ATCC) NEO-101 NPC-1C, NPC-1 Light Chain (SEQ ID NOs: 14, 15) Chimeric NPC-1 antibody, ensituximab LC CDRs (SEQ ID NOs: 16, 17, 18 engineered in CHO-DG44 Heavy Chain (SEQ ID NOs: 19, 20) production cell clone 4B7; HC CDRs (SEQ ID NOs: 21, 22, 23) targets a variant of MUC5AC NEO-102 NPC-1 Light Chain (SEQ ID NOs: 24, 25) Chimeric NPC-1 antibody, LC CDRs (SEQ ID NOs: 26, 27, 28) engineered in CHO-M Heavy Chain (SEQ ID NOs: 29, 30) production cells, contains 2 HC CDRs (SEQ ID NOs: 31, 32, 33) amino acid changes in HC constant domain* NEO-103 NPC-1 Light Chain (SEQ ID NOs: 34, 35) Humanized NPC-1 antibody Heavy Chain (SEQ ID NOs: 36, 37) 16C3 16C3 Light Chain (SEQ ID NOs: 38, 39) Murine hybridoma that LC CDRs (SEQ ID NOs: 40, 41, 42) expresses 16C3 IgG1 (ATCC) Heavy Chain (SEQ ID NOs: 43, 44) HC CDRs (SEQ ID NOs: 45, 46, 47) 16C3 Variant 16C3 Light Chain (SEQ ID NOs: 48, 49, Humanized 16C3 antibody h16C3 50, 51, 52) antibodies Heavy Chain (SEQ ID NOs: 53, 54, 55, 56, 57) NEO-201 h16C3- 16C3 Light Chain (SEQ ID NOs: 58, 59) Humanized 16C3 antibody Abb* LC CDRs (SEQ ID NOs: 60, 61, 62) Heavy Chain (SEQ ID NOs: 63, 64) HC CDRs (SEQ ID NOs: 65, 66, 67) NEO-300 Antibodies 31.1 31.1 Chimeric 31.1 antibody, produced in CHO-K cells NEO-301 31.1C 31.1 Light Chain (SEQ ID NO: 68) Chimeric 31.1 antibody, Heavy Chain (SEQ ID NO: 69) contains 2 amino acid changes in HC constant domain,* produced in high titer CHO-S cells NEO-302 31.1 Light Chain (SEQ ID NO: 70, 71) Humanized 31.1 antibody Heavy Chain (SEQ ID NO: 72, 73) NEO-303 31.1 Heavy Chain (SEQ ID NOs: 74-77) Humanized 31.1 antibody HC CDRs (SEQ ID NOs: 78-83) Light Chain (SEQ ID NOs: 84-87) LC CDRs (SEQ ID NOs: 88-93) *2 amino acid changes in heavy chain constant domain are Proline at residue 175 to Leucine in CH1 and Methionine at residue 390 to Threonine in CH3. ..

Residue:

Article Title: Humanized monoclonal antibodies and methods of use for the diagnosis and treatment of colon and pancreas cancer
Article Snippet: .. TABLE 1 Antibodies Antibody Aliases Antigen Exemplary SEQ ID NOs Description NPC-1 NPC-1 Murine hybridoma that expresses NPC-1 IgG1 (ATCC) NEO-101 NPC-1C, NPC-1 Light Chain (SEQ ID NOs: 14, 15) Chimeric NPC-1 antibody, ensituximab LC CDRs (SEQ ID NOs: 16, 17, 18 engineered in CHO-DG44 Heavy Chain (SEQ ID NOs: 19, 20) production cell clone 4B7; HC CDRs (SEQ ID NOs: 21, 22, 23) targets a variant of MUC5AC NEO-102 NPC-1 Light Chain (SEQ ID NOs: 24, 25) Chimeric NPC-1 antibody, LC CDRs (SEQ ID NOs: 26, 27, 28) engineered in CHO-M Heavy Chain (SEQ ID NOs: 29, 30) production cells, contains HC CDRs (SEQ ID NOs: 31,32, 33) 2 amino acid changes in HC constant domain* NEO-103 NPC-1 Light Chain (SEQ ID NOs: 34, 35) Humanized NPC-1 antibody Heavy Chain (SEQ ID NOs: 36, 37) 16C3 16C3 Light Chain (SEQ ID NOs: 38, 39) Murine hybridoma that LC CDRs (SEQ ID NOs: 40, 41, 42) expresses 16C3 IgG1 Heavy Chain (SEQ ID NOs: 43, 44) (ATCC) HC CDRs (SEQ ID NOs: 45, 46, 47) 16C3 Variant 16C3 Light Chain (SEQ ID NOs: 48, Humanized 16C3 antibody h16C3 49, 50, 51, 52) antibodies Heavy Chain (SEQ ID NOs: 53, 54, 55, 56, 57) NEO-201 h16C3-Abb* 16C3 Light Chain (SEQ ID NOs: 58, 59) Humanized 16C3 antibody LC CDRs (SEQ ID NOs: 60, 61, 62) Heavy Chain (SEQ ID NOs: 63, 64) HC CDRs (SEQ ID NOs: 65, 66, 67) NEO-300 Antibodies 31.1 31.1 Chimeric 31.1 antibody, produced in CHO-K cells NEO-301 31.1C 31.1 Light Chain (SEQ ID NO: 68) Chimeric 31.1 antibody, Heavy Chain (SEQ ID NO: 69) contains 2 amino acid changes in HC constant domain,* produced in high titer CHO-S cells NEO-302 31.1 Light Chain (SEQ ID NO: 70, 71) Humanized 31.1 antibody Heavy Chain (SEQ ID NO: 72, 73) NEO-303 31.1 Heavy Chain (SEQ ID NOs: 74-77) Humanized 31.1 antibody HC CDRs (SEQ ID NOs: 78-83) Light Chain (SEQ ID NOs: 84-87) LC CDRs (SEQ ID NOs: 88-93) *2 amino acid changes in heavy chain constant domain are Proline at residue 175 to Leucine in CH1 and Methionine at residue 390 to Threonine in CH3. ..

Article Title: Humanized monoclonal antibodies and methods of use for the diagnosis and treatment of colon and pancreas cancer
Article Snippet: .. TABLE 1 Antibodies Antibody Aliases Antigen Exemplary SEQ ID NOs Description NPC-1 NPC-1 Murine hybridoma that expresses NPC-1 IgG1 (ATCC) NEO-101 NPC-1C, NPC-1 Light Chain (SEQ ID NOs: 14, 15) Chimeric NPC-1 antibody, ensituximab LC CDRs (SEQ ID NOs: 16, 17, 18 engineered in CHO-DG44 Heavy Chain (SEQ ID NOs: 19, 20) production cell clone 4B7; HC CDRs (SEQ ID NOs: 21, 22, 23) targets a variant of MUC5AC NEO-102 NPC-1 Light Chain (SEQ ID NOs: 24, 25) Chimeric NPC-1 antibody, LC CDRs (SEQ ID NOs: 26, 27, 28) engineered in CHO-M Heavy Chain (SEQ ID NOs: 29, 30) production cells, contains 2 HC CDRs (SEQ ID NOs: 31, 32, 33) amino acid changes in HC constant domain* NEO-103 NPC-1 Light Chain (SEQ ID NOs: 34, 35) Humanized NPC-1 antibody Heavy Chain (SEQ ID NOs: 36, 37) 16C3 16C3 Light Chain (SEQ ID NOs: 38, 39) Murine hybridoma that LC CDRs (SEQ ID NOs: 40, 41, 42) expresses 16C3 IgG1 (ATCC) Heavy Chain (SEQ ID NOs: 43, 44) HC CDRs (SEQ ID NOs: 45, 46, 47) 16C3 Variant 16C3 Light Chain (SEQ ID NOs: 48, 49, Humanized 16C3 antibody h16C3 50, 51, 52) antibodies Heavy Chain (SEQ ID NOs: 53, 54, 55, 56, 57) NEO-201 h16C3- 16C3 Light Chain (SEQ ID NOs: 58, 59) Humanized 16C3 antibody Abb* LC CDRs (SEQ ID NOs: 60, 61, 62) Heavy Chain (SEQ ID NOs: 63, 64) HC CDRs (SEQ ID NOs: 65, 66, 67) NEO-300 Antibodies 31.1 31.1 Chimeric 31.1 antibody, produced in CHO-K cells NEO-301 31.1C 31.1 Light Chain (SEQ ID NO: 68) Chimeric 31.1 antibody, Heavy Chain (SEQ ID NO: 69) contains 2 amino acid changes in HC constant domain,* produced in high titer CHO-S cells NEO-302 31.1 Light Chain (SEQ ID NO: 70, 71) Humanized 31.1 antibody Heavy Chain (SEQ ID NO: 72, 73) NEO-303 31.1 Heavy Chain (SEQ ID NOs: 74-77) Humanized 31.1 antibody HC CDRs (SEQ ID NOs: 78-83) Light Chain (SEQ ID NOs: 84-87) LC CDRs (SEQ ID NOs: 88-93) *2 amino acid changes in heavy chain constant domain are Proline at residue 175 to Leucine in CH1 and Methionine at residue 390 to Threonine in CH3. ..

Review